Friday, June 9, 2023

ASCO23 Day 4 (6/5/23) Gyn Cancer Posters, Poster Discussion session & Misc topics

Note: Due to the number of Tweets embedded in this post the page may take some time to load.  

Monday's sessions included the Gyn Cancer Poster session and the Poster Discussion session. There were a few other sessions that I found interesting and are included at the end of this post. 

Poster Discussion Session

Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC). ABSTRACT 5515
 
Randomized phase 2 study of gemcitabine with or without ATR inhibitor berzosertib in platinum-resistant ovarian cancer: Final overall survival (OS) and biomarker analyses. ABSTRACT 5512
"Gemcitabine/berzosertib did not significantly improve OS versus gemcitabine alone. Pts with PFI≤3 months and pts with RS-low tumors may derive a survival advantage from addition of berzosertib to gemcitabine in the platinum-resistant setting. Clinical trial information: NCT02595892."
 
Correlation of cyclin E1 expression and clinical outcomes in a phase 1b dose-escalation study of azenosertib (ZN-c3), a WEE1 inhibitor, in combination with chemotherapy (CT) in patients (pts) with platinum-resistant or refractory (R/R) epithelial ovarian, peritoneal, or fallopian tube cancer (EOC). ABSTRACT 5513
"Study assessed azenosertib + paclitaxel (PAC), carboplatin (Carbo), gemcitabine (GEM), or pegylated liposomal doxorubicin (PLD) in pts with metastatic high-grade serous EOC after ≤2 lines of chemotherapy. Patients with Cyclin E1 overexperessing tumors, a subgroup with suboptimal benefits from chemo , demonstrated significant imporovements in ORR and PFS vs patients with tumors having low expresssion."

 
A phase II trial of palbociclib combined to letrozole after progression on second-line chemotherapy for women with ER/PR-positive high-grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer: LACOG 1018.  ABSTRACT 5541
"Palbociclib combined to letrozole demonstrated a significant efficacy in terms of PFS rate at 12 weeks (63.4%) and CBR (71.8%), with no new safety concerns in women with recurrent advanced and metastatic hormone receptor-positive ovarian cancer. These results warrant further investigation of palbociclib plus letrozole in high-grade ovarian cancer."
The Normal Risk Ovarian Screening Study (NROSS): Twenty-one year update. ABSTRACT 5522
"A total of 7,856 healthy postmenopausal women were screened annually for a total of 50,596 women-years in a single arm study (NCT00539162). Serum CA125 was analyzed with the Risk of Ovarian Cancer Algorithm (ROCA) each year....An elevated ROCA, characterized by a significantly rising CA125, prompted referral of 2% of participants to transvaginal sonography (TVS) each year and required only 2 operations to detect each case of ovarian cancer, indicating that CA125 used in this way is adequately specific for effective screening.
Posters
Here are a few posters I found interesting that were not part of the discussion session. 

Efficacy and safety of niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer who had measurable residual disease: A post-hoc subgroup analysis of the PRIME study. ABSTRACT 5562

"This study aims to report the efficacy, including antitumor activity, and safety of niraparib maintenance therapy in patients with measurable residual disease MRD after first-line platinum-based chemotherapy1LCT from the phase 3 PRIME trial. ...  Median PFS (95% CI) was 22.3 (8.7–not estimable) months with niraparib versus 8.3 (5.6–11.0) months with placebo (hazard ratio, 0.36; 95% CI, 0.19–0.71)."


Circulating tumor DNA (ctDNA) as a marker of residual disease and recurrence in resected stage I-IV epithelial ovarian cancer (EOC). ABSTRACT 5553
ctDNA detection after ovarian cancer cytoreduction identifies pts at very high risk of recurrence. Pts with BRCA mutations were more likely to have negative ctDNA post-op. The role of ctDNA in guiding neoadjuvant and adjuvant therapy to improve outcomes, warrants further investigation. Clinical trial information: ACTRN12617001119381.
 

Safety and efficacy of PIPAC in ovarian cancer patients with peritoneal metastases: A first-in-US phase I study.  ABSTRACT 5554

"Pressurized intraperitoneal aerosolized chemotherapy (PIPAC) is a novel IP drug delivery method that optimizes tissue penetration depth and drug distribution, to treat recurrent peritoneal malignancies. 

PIPAC with cisplatin/doxorubicin in platinum-resistant ovarian cancer is well tolerated. Intraperitoneal responses were seen in a subset of low-grade serous ovarian cancer patients, which may warrant further study."



 

Miscellaneous ASCO topics: 

Patient Centered Research

Solid tumor research

Destiny Pan-Tumor-02
Her-2 expressing tumors -trastuzumab deruxtecan (T-DXd)

 

This brings my highlights from the ASCO 2023 Annual meeting to a close. I hope to see everyone in person next year!

 Dee

Every Day is a Blessing ! 

Posted by at No comments:
Labels: , , , , , , , , , , , ,

Thursday, June 8, 2023

ASCO23 Day 3 :Parp Inhibitors & Late Breaking Abstract session

While there were fewer gynecologic cancer sessions on Day 3, Sunday June 4th there were two important sessions regarding the use of PARP inhibitors and trial results for a drug to teat  platinum resistant ovarian cancer drug which may be change practice.

Parp Inhibitor Optimal Selection and Toxicity Management 

Dr Tew - Status updates on Parp use


Dr Friedlander- Real World Experience in Managing PARP Toxicities 


 


 


 Susan Feinberg  (FORCE) - Living on a PARPi 


 


Late Breaking Abstract Session  
Mirvetixumab in Folate Receptor Alpha positive platinum resistant ovarian cancer

I wish I had been able to be in the room when this session took place. I could feel the excitement from the Tweets being posted.  This is the first trial to show overall survival benefit in platinum resistant ovarian cancer! This is practice changing. 

 Here is a slide of the overall survival  MIRV 16.46 months vs investigator choice of treatment 12.75 months.


 Stop by tomorrow for highlights from my last day of ASCO - Day 4 . 


Dee

Every Day is a Blessing

Posted by at No comments:
Labels: , , , , , , ,

Wednesday, June 7, 2023

ASCO 2023 Day 2: Opening Session, GTD Panel , Gyn Cancer Oral Abstract session

Note: Due to the number of Tweets embedded in this post the page may take some time to load.

Saturday was a busy day at #ASCO23. For me it included live sessions, on-demand sessions and two meetings. 

 Opening Session

 

 

 

The session finished with a chat with the Surgeon General, Dr Vivak Murphy who discussed a range of topics. 


 Case-based Panel - GTD

This session which talked about a Gestational Trophoblastic Disease ( GTD) a rare gyn cancer. I viewed on-demand the day after the presentation. 


Oral Abstract Session

Cervical Cancer - Keynote 826

 

 Ovarian cancer

 Ofranergene obadenove + weekly taxol

GOG 3025 -durvalumab + olaparib + bevacizumab

Luveltamab tazevibulin (STRO-002)


Endometrial Cancer 

 

Did I miss any important gyn studies? Please note them in the comment box. Thanks

Check back tomorrow for highlights from Day 3. 


Dee

Every Day is a Blessing!

Posted by at No comments:
Labels: , , , , , , , , , , ,

Monday, June 5, 2023

ASCO 2023: Day 1- Cervical Cancer, HIPEC, Antibody Drug Conjugates in Gyn Cancers

Note: Due to the number of Tweets embedded in this post the page may take some time to load.

This year I attended #ASCO23 virtually. Some of the sessions were available live but some were on-demand usually a day later. Many of the Tweets I will share in the next few posts were from those I follow who attended those sessions in person. 

Friday, June 2,2023

Clinical Science Symposium  

Cervical Cancer 

An international randomized phase III trial comparing radical hysterectomy and pelvic node dissection (RH) vs simple hysterectomy and pelvic node dissection (SH) in patients with low-risk early-stage cervical cancer (LRESCC):  A Gynecologic Cancer Intergroup study led by the Canadian Cancer Trials Group (CCTG CX.5-SHAPE).       Abtract LBA 5511


 Read more about the above study at https://www.cancer.net/blog/2023-06/asco-annual-meeting-2023-less-extensive-hysterectomy-effective-early-cervical-cancer-and-adding?cmpid=ks_cancernet_net_awareness_sno_facebook_all__glob_060223____aware_photo-text_ 

 

 

 HIPEC in Ovarian Cancer

Final survival analysis of the phase III OVHIPEC-1 trial of hyperthermic intraperitoneal chemotherapy in ovarian cancer after ten year follow-up. (Sonke  abstract 5509) 
Median follow up of 10.1 years. "One hundred and eight patients (87.8%) in the surgery group have died as compared to 100 patients (82.0%) in the surgery-plus-HIPEC group.Median recurrence-free survival was 10.7 months in the surgery group compared to 14.3 months in the surgery-plus-HIPEC group (HR, 0.63; 95% confidence interval [CI], 0.48-0.83; stratified P<0.001). This study provides the first long-term survival analysis of HIPEC in ovarian cancer and confirms the benefit of HIPEC in patients with primary stage III epithelial ovarian cancer undergoing interval cytoreductive surgery. "                                   Overall survival 44.9 with HIPEC versus 33.3 no HIPEC. 
Hyperthermic intraperitoneal chemotherapy in platinum-sensitive relapsed epithelial ovarian cancer: The CHIPOR randomized phase III trial. (abstract 5510)
"The CHIPOR multicentric randomized phase III trial (NCT01376752), conducted in 31 institutions, enrolled patients with a first platinum-sensitive relapse (platinum-free interval of ≥6 months) of EOC. Patients were treated with 6 cycles of platinum and taxane based CT ± bevacizumab, and those amenable to a complete cytoreductive surgery at the end of CT were enrolled and randomly assigned to receive HIPEC (cisplatin 75 mg/m² at 41°C for 60 min) or not. HIPEC significantly improves OS and peritoneal PFS of women with first platinum-sensitive relapse of EOC treated with second-line platinum-based CT followed by secondary complete cytoreductive surgery."
 
 
Education Session 
 Antibody Drug Conjugates: New Opportunities in Gynecologic Cancer

 


 




Dee

Every Day is a Blessing!

Posted by at No comments:
Labels: , , , , , , ,
Subscribe to: Posts (Atom)